Tildrakizumab was shown to be efficacious in treating moderate-to-severe plaque psoriasis on the scalp.

Topical treatment decreases itch and improves sleep patterns in patients with psoriasis and atopic dermatitis.

The visibility of a skin disorder is directly linked to stigma including bullying.

Early-life antibiotic use affects the gut microbiome which may lead to an increase risk of AD.

Hidradenitis suppurativa patients are at higher risk for respiratory diseases.

Suicidal ideation and behaviour and depression are low and within general psoriasis ranges in patients being treated with bimekizumab.

There are significant delays in diagnosis and low implementation rates for treatment for HS.

Topical melatonin and topical rosuvastatin were both effective in reducing the severity of mild-to-moderate plaque PsO.